Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors
← catalyst calendarNCT05651022 · readout in 315 d
Sponsored by Indaptus Therapeutics, Inc (industry) · INDP — their whole pipeline →. With Translational Drug Development.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
120estimated
Sites
12
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-02-28 | actual | When the study began enrolling |
| Primary completion | 2027-06-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-09-30 | estimated | The whole study's end, after follow-up |
| First posted | 2022-12-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Solid Tumor, Adult
- HCC - Hepatocellular Carcinoma
- CRC (Colorectal Cancer)
- Pancreatic Adenocarcinoma
- NSCLC Non-small Cell Lung Cancer
- Squamous Cell Cancer of the Head and Neck
- UC (Urothelial Cancer)
- MSI-H Cancer
Interventions
- Drug: Decoy20
- Drug: Tislelizumab
Primary outcomes
what the primary-completion date above is the date OFNumber of Subjects with dose-limiting toxicities (DLTs)
measured Through study completion, up to 3 years
Percentage of subjects with Adverse Events (AEs)
measured Through completion, up to 3 years
Maximum Tolerated Dose (MTD) of Decoy20
measured Up to 2 years
Recommended Phase 2 Dose (RP2D) of Decoy20
measured Up to 2.5 years
Publications
- PMID 39606250 — cited as background
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · INDP's whole pipeline · Catalyst calendar · Every registered study · What changed